|
US4602705A
(en)
|
1981-11-09 |
1986-07-29 |
Lucas Industries Public Limited Company |
Flywheel mechanism for anti-skid braking systems
|
|
US5364773A
(en)
|
1991-03-07 |
1994-11-15 |
Virogenetics Corporation |
Genetically engineered vaccine strain
|
|
US4652639A
(en)
|
1982-05-06 |
1987-03-24 |
Amgen |
Manufacture and expression of structural genes
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US6100064A
(en)
|
1984-04-06 |
2000-08-08 |
Chiron Corporation |
Secreted viral proteins useful for vaccines and diagnostics
|
|
US6610476B1
(en)
|
1984-08-22 |
2003-08-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
Detection of HIV-1 DNA
|
|
US5032510A
(en)
|
1984-09-26 |
1991-07-16 |
Eli Lilly And Company |
Method for expression and secretion in bacillus
|
|
CA1341482C
(en)
|
1984-10-31 |
2005-05-10 |
Paul A. Luciw |
Process for preparing fragments of aids-associated retroviruses
|
|
WO1986003224A1
(en)
|
1984-11-29 |
1986-06-05 |
Scripps Clinic And Research Foundation |
Polypeptides and antibodies related to deglycosylated viral glycoproteins
|
|
ATE138100T1
(de)
|
1984-12-24 |
1996-06-15 |
Genentech Inc |
Fusionen von aids-verwandten polypeptiden
|
|
NZ215867A
(en)
|
1985-04-19 |
1989-10-27 |
Hoffmann La Roche |
Aids envelope protein, dna vectors and method of production
|
|
EP0245362B1
(en)
|
1985-10-24 |
1994-06-29 |
Ronald C. Kennedy |
Synthetic peptides and use for diagnosis and vaccination for aids and arc
|
|
EP0242216A1
(en)
|
1986-04-16 |
1987-10-21 |
THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce |
Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III
|
|
AU7786387A
(en)
|
1986-07-21 |
1988-02-10 |
Southwest Foundation For Biomedical Research |
Composition of matter and method of immunizing against viral causative agents of aids and arc
|
|
US4861707A
(en)
|
1987-02-02 |
1989-08-29 |
E. I. Du Pont De Nemours And Company |
Human immunodeficiency virus antigen
|
|
US5256767A
(en)
|
1987-06-10 |
1993-10-26 |
The Immune Response Corporation |
Retroviral antigens
|
|
IL86832A
(en)
|
1987-06-22 |
2002-09-12 |
Medeva Holdings Bv |
A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it
|
|
US5637677A
(en)
|
1987-07-16 |
1997-06-10 |
The Trustees Of The University Of Pennsylvania |
Biologically active compounds and methods of constructing and using the same
|
|
WO1989002277A2
(en)
|
1987-08-28 |
1989-03-23 |
Board Of Regents, The University Of Texas System |
Prophylaxis and therapy of acquired immunodeficiency syndrome
|
|
US5128319A
(en)
|
1987-08-28 |
1992-07-07 |
Board Of Regents, The University Of Texas System |
Prophylaxis and therapy of acquired immunodeficiency syndrome
|
|
EP0347435A4
(en)
|
1987-09-04 |
1991-11-21 |
Biogen, Inc. |
Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
|
|
US5879907A
(en)
|
1987-09-14 |
1999-03-09 |
Skandigen Ab |
Artificial gene coding for authentic human serum albumin, use thereof and method
|
|
NZ226414A
(en)
|
1987-10-02 |
1992-07-28 |
Genentech Inc |
Cd4 peptide adhesion variants and their preparation and use
|
|
IL87902A0
(en)
|
1987-10-08 |
1989-03-31 |
Dana Farber Cancer Inst Inc |
Soluble human cd4 fragments and applications thereof
|
|
US5712088A
(en)
|
1987-11-18 |
1998-01-27 |
Chiron Corporation |
Methods for detecting Hepatitis C virus using polynucleotides specific for same
|
|
US5714596A
(en)
|
1987-11-18 |
1998-02-03 |
Chiron Corporation |
NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
|
|
US5683864A
(en)
|
1987-11-18 |
1997-11-04 |
Chiron Corporation |
Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
|
|
US5204259A
(en)
|
1988-05-06 |
1993-04-20 |
Pharmacia Genetic Engineering, Inc. |
Methods and systems for producing HIV antigens
|
|
CA1340748C
(en)
|
1988-07-13 |
1999-09-14 |
Stephen Oroszlan |
Synthetic hiv protease gene and method for its expression
|
|
WO1990002568A1
(en)
|
1988-09-13 |
1990-03-22 |
Chiron Corporation |
Hiv-1 envelope muteins lacking hypervariable domains
|
|
WO1990003984A1
(en)
|
1988-10-03 |
1990-04-19 |
Repligen Corporation |
Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
|
|
CA2003383A1
(en)
|
1988-11-23 |
1990-05-23 |
Sushil G. Devare |
Synthetic dna derived recombinant hiv antigens
|
|
AU5184190A
(en)
|
1989-02-23 |
1990-09-26 |
University Of Ottawa |
Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
|
|
US5082767A
(en)
|
1989-02-27 |
1992-01-21 |
Hatfield G Wesley |
Codon pair utilization
|
|
IL93682A
(en)
|
1989-03-16 |
1996-06-18 |
Yeda Res & Dev |
Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
|
|
WO1990011359A1
(en)
|
1989-03-20 |
1990-10-04 |
Whitehead Institute For Biomedical Research |
Intracellular method of inhibiting hiv in mammalian cells
|
|
DK0737750T3
(da)
|
1989-03-21 |
2003-09-01 |
Vical Inc |
Ekspression af exogene polynucleotidsekvenser i vertebrater
|
|
US6214804B1
(en)
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
|
WO1990012094A1
(en)
|
1989-04-05 |
1990-10-18 |
The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce |
A clone of double-stranded rna virus and applications thereof
|
|
EP0431128B1
(en)
|
1989-06-01 |
2003-03-26 |
Applied Biotechnology, Inc. |
Vector coding for self-assembled, defective, non-self-propagating viral particles
|
|
US5130247A
(en)
|
1989-09-19 |
1992-07-14 |
Merck & Co., Inc. |
Expression of fusion protein of HIV envelope and HBsAG
|
|
AU6523590A
(en)
|
1989-09-22 |
1991-04-18 |
Idec Pharmaceuticals Corporation |
Novel peptides associated with the cd4 binding region of gp120 and their methods of use
|
|
DE69019291T2
(de)
|
1989-10-23 |
1995-09-21 |
F. Hoffmann-La Roche Ag, Basel |
Synthetische HTLV-I Hüll-Peptide.
|
|
DE69032484D1
(de)
|
1989-10-27 |
1998-08-20 |
Arch Dev Corp |
Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
|
|
AU6965591A
(en)
|
1989-11-17 |
1991-06-13 |
Amgen, Inc. |
A method of detecting htlv-i antibodies in human body fluids
|
|
HUT60506A
(en)
|
1989-11-20 |
1992-09-28 |
Oncogen |
Process for producing non-replicable, recombinant retrovirus particles and antiviral and immunogenic preparations
|
|
SE468168B
(sv)
|
1990-02-20 |
1992-11-16 |
Replico Medical Ab |
Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
|
|
IE910779A1
(en)
|
1990-03-09 |
1991-09-11 |
Chiron Corp |
PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION
|
|
US5876724A
(en)
|
1990-03-19 |
1999-03-02 |
Institut Pasteur |
Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
|
|
ATE183235T1
(de)
|
1990-03-21 |
1999-08-15 |
Wolf Hans Joachim Prof Dr |
Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
|
|
AU647108B2
(en)
|
1990-04-03 |
1994-03-17 |
Genentech Inc. |
Methods and compositions for vaccination against HIV
|
|
AU7676891A
(en)
|
1990-04-03 |
1991-10-30 |
Genentech Inc. |
Hiv envelope polypeptides
|
|
IL97985A0
(en)
|
1990-05-07 |
1992-06-21 |
North American Vaccine Inc |
Improved vaccine compositions
|
|
AP237A
(en)
|
1990-05-29 |
1993-04-29 |
Cedars Sinai Medical Center |
Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
|
|
WO1991019803A1
(en)
|
1990-06-19 |
1991-12-26 |
Applied Biotechnology, Incorporated |
Self assembled, defective, nonself-propagating viral particles
|
|
EP0551308A4
(en)
|
1990-08-29 |
1994-09-14 |
Us Health |
Novel peptide antigens and immunoassays, test kits and vaccines using the same
|
|
US5840313A
(en)
|
1990-09-27 |
1998-11-24 |
Syntello Vaccine Development Kb |
Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
|
|
AU653366B2
(en)
|
1990-09-28 |
1994-09-29 |
Hospital For Joint Diseases |
Method for inhibiting the infectivity of human immunodeficiency virus
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
PT100090A
(pt)
|
1991-02-04 |
1993-07-30 |
Univ Saskatchewan |
Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
|
|
JPH06508821A
(ja)
|
1991-03-07 |
1994-10-06 |
セラジュン インク |
ウイルス病治療のための細胞表面受容体を標的とする分子の使用
|
|
US6139843A
(en)
|
1991-04-02 |
2000-10-31 |
Albert Einstein College Of Medicine Of Yeshiva University |
Peptide compositions for the treatment of HIV
|
|
AU2412692A
(en)
|
1991-07-23 |
1993-02-23 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Novel peptide antigens and immunoassays, test kits and vaccines using the same
|
|
US5558865A
(en)
|
1991-08-22 |
1996-09-24 |
Nissin Shokuhin Kabushiki Kaisha |
HIV immunotherapeutics
|
|
WO1993004090A1
(en)
|
1991-08-22 |
1993-03-04 |
Nissin Shokuhin Kabushiki Kaisha |
Hiv immunotherapeutics
|
|
DK0608261T3
(da)
|
1991-09-13 |
2003-03-17 |
Chiron Corp |
Sammensætninger med immunreaktivt hepatitis C virus polypeptid
|
|
EP0613378A1
(en)
|
1991-10-28 |
1994-09-07 |
Institut Pasteur |
Induction of protection against viral infection by synergy between viral proteins and viral peptides
|
|
AU3483293A
(en)
|
1992-01-22 |
1993-09-01 |
New England Medical Center Hospitals, Inc., The |
Pathogen-specific CTL therapy
|
|
US5174666A
(en)
|
1992-02-12 |
1992-12-29 |
Smith Corona Corporation |
Printing device having printwheel coupling means
|
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
|
WO1993021346A1
(en)
|
1992-04-09 |
1993-10-28 |
Abbott Laboratories |
Assay for detection of hiv antigen and hiv antibody
|
|
CA2135646A1
(en)
|
1992-05-11 |
1993-11-25 |
Kenneth G. Draper |
Method and reagent for inhibiting viral replication
|
|
US5663169A
(en)
|
1992-08-07 |
1997-09-02 |
Merck & Co., Inc. |
Benzoxazinones as inhibitors of HIV reverse transcriptase
|
|
DE4228458A1
(de)
|
1992-08-27 |
1994-06-01 |
Beiersdorf Ag |
Multicistronische Expressionseinheiten und deren Verwendung
|
|
FR2695563B1
(fr)
|
1992-09-11 |
1994-12-02 |
Pasteur Institut |
Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
|
|
US6004763A
(en)
|
1992-09-11 |
1999-12-21 |
Institut Pasteur |
Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
|
|
CA2105629A1
(en)
|
1992-09-14 |
1994-03-15 |
Robert S. Becker |
Potentiation of immunogenic response
|
|
US5686078A
(en)
|
1992-09-14 |
1997-11-11 |
Connaught Laboratories, Inc. |
Primary and secondary immunization with different physio-chemical forms of antigen
|
|
ES2194015T3
(es)
|
1992-09-30 |
2003-11-16 |
Scripps Research Inst |
Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
|
|
US5652138A
(en)
|
1992-09-30 |
1997-07-29 |
The Scripps Research Institute |
Human neutralizing monoclonal antibodies to human immunodeficiency virus
|
|
US5648267A
(en)
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
|
US5304472A
(en)
|
1992-11-20 |
1994-04-19 |
Genentech, Inc. |
Method of controlling polypeptide production in bacterial cells
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
WO1994016060A1
(en)
|
1993-01-11 |
1994-07-21 |
The Trustees Of The University Of Pennsylvania |
Mutants of hiv for supression of hiv infection
|
|
AU692433B2
(en)
|
1993-01-13 |
1998-06-11 |
Arsinur Burcoglu |
Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
|
|
US6140059A
(en)
|
1993-01-16 |
2000-10-31 |
Schawaller; Manfred |
Methods for the obtention of human immunodeficiency virsus Type 1 envelope glycoproteins in native and oligomeric form employing recombinant chimeric antigens containing collagenase recognition sites.
|
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
|
ES2249760T3
(es)
|
1993-01-26 |
2006-04-01 |
The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) |
Composiciones y procedimientos de administracion de materias geneticas.
|
|
WO1994018221A1
(en)
|
1993-02-02 |
1994-08-18 |
The Scripps Research Institute |
Methods for producing polypeptide binding sites
|
|
AU6359794A
(en)
|
1993-03-05 |
1994-09-26 |
Genelabs Technologies, Inc. |
Method for hiv quantitation
|
|
NZ263373A
(en)
|
1993-03-11 |
1997-05-26 |
Univ Southern California |
Monoclonal antibodies and use against immunoinfective cluster viruses
|
|
JP4108118B2
(ja)
|
1993-03-26 |
2008-06-25 |
ジェン−プローブ・インコーポレイテッド |
ヒト・免疫不全ウイルス1型の検出
|
|
US5869624A
(en)
|
1993-03-26 |
1999-02-09 |
Progenics Pharmaceuticals, Inc. |
HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
|
|
KR960701988A
(ko)
|
1993-04-20 |
1996-03-28 |
윌리엄 에스. 로빈슨 |
세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
|
|
US5419900A
(en)
|
1993-05-19 |
1995-05-30 |
The United States Of America As Represented By The Department Of Of Health And Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
|
WO1994028929A1
(en)
|
1993-06-07 |
1994-12-22 |
Genentech, Inc. |
Hiv envelope polypeptides
|
|
AU693098B2
(en)
|
1993-06-09 |
1998-06-25 |
Connaught Laboratories Limited |
Tandem synthetic HIV-1 peptides
|
|
CA2125344A1
(en)
|
1993-07-01 |
1995-01-02 |
Casey D. Morrow |
Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
|
|
US5614413A
(en)
|
1993-07-01 |
1997-03-25 |
The Uab Research Foundation |
Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
|
|
ATE239787T1
(de)
|
1993-07-19 |
2003-05-15 |
Gen Probe Inc |
Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
|
|
WO1995004818A1
(en)
|
1993-08-06 |
1995-02-16 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for inhibiting human immunodeficiency virus replication
|
|
CA2174532A1
(en)
|
1993-10-19 |
1995-04-27 |
Carlos F. Barbas |
Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
|
|
JPH09504296A
(ja)
|
1993-10-26 |
1997-04-28 |
シンテロ インコーポレイテッド |
Hiv粘膜感染の阻止
|
|
IL112820A0
(en)
|
1994-03-07 |
1995-05-26 |
Merck & Co Inc |
Coordinate in vivo gene expression
|
|
CA2185129A1
(en)
|
1994-03-14 |
1995-09-21 |
Angeline Douvas |
Methods to diagnose and treat hiv-1 infection
|
|
AU2247095A
(en)
|
1994-04-12 |
1995-10-30 |
Biomira Inc. |
Cellular immune response-specific antigens and uses therefor
|
|
DE69527708T2
(de)
|
1994-04-29 |
2003-04-30 |
Duke University, Durham |
Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
|
|
WO1995033206A1
(en)
|
1994-05-31 |
1995-12-07 |
Abbott Laboratories |
Detection of different hiv genotypes utilizing a synthetic peptide-modified immunoassay
|
|
WO1995033835A1
(en)
|
1994-06-02 |
1995-12-14 |
Chiron Corporation |
Nucleic acid immunization using a virus-based infection/transfection system
|
|
US5733781A
(en)
|
1994-07-19 |
1998-03-31 |
Gen-Probe Incorporated |
Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
|
|
US5955342A
(en)
|
1994-08-15 |
1999-09-21 |
Connaught Laboratories Limited |
Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
|
|
US6291157B1
(en)
|
1998-02-23 |
2001-09-18 |
Connaught Laboratories Limited |
Antigenically-marked non-infectious retrovirus-like particles
|
|
US6080408A
(en)
|
1994-08-22 |
2000-06-27 |
Connaught Laboratories Limited |
Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
|
|
US5795737A
(en)
|
1994-09-19 |
1998-08-18 |
The General Hospital Corporation |
High level expression of proteins
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
WO1996009066A2
(en)
|
1994-09-23 |
1996-03-28 |
The Johns Hopkins University School Of Medicine |
Method of treatment of human immunodeficiency virus (hiv) infection
|
|
MX9703676A
(es)
|
1994-11-17 |
1998-03-31 |
Maxim Pharm Inc |
Inmunogenos para estimular la inmunidad de las mucosas.
|
|
US5550280A
(en)
|
1994-11-30 |
1996-08-27 |
Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee |
Hindered aromatic ester compounds useful as anti-viral agents
|
|
JPH10512243A
(ja)
|
1994-12-30 |
1998-11-24 |
カイロン コーポレイション |
遺伝子送達ビヒクルの非外傷性投与
|
|
US6689761B1
(en)
|
1995-02-01 |
2004-02-10 |
Merck & Co., Inc. |
Combination therapy for HIV infection
|
|
FR2730411B1
(fr)
|
1995-02-14 |
1997-03-28 |
Centre Nat Rech Scient |
Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
|
|
CN1185811A
(zh)
|
1995-03-31 |
1998-06-24 |
H·沃尔夫 |
依赖于逆转录病毒样颗粒的抗原呈递系统
|
|
US5797870A
(en)
|
1995-06-07 |
1998-08-25 |
Indiana University Foundation |
Pericardial delivery of therapeutic and diagnostic agents
|
|
US6251405B1
(en)
|
1995-06-07 |
2001-06-26 |
Connaught Laboratories, Inc. |
Immunological combination compositions and methods
|
|
WO1997003198A2
(en)
|
1995-07-07 |
1997-01-30 |
Texas A & M University System |
Nucleotide and amino acid sequence and uses thereof
|
|
WO1997011605A1
(en)
|
1995-09-28 |
1997-04-03 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
|
|
AU1750497A
(en)
|
1996-01-17 |
1997-08-11 |
Progenics Pharmaceuticals, Inc. |
Compounds capable of inhibiting hiv-1 infection
|
|
CU22559A1
(es)
|
1996-01-17 |
1999-05-03 |
Ct Ingenieria Genetica Biotech |
Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
|
|
US5741492A
(en)
|
1996-01-23 |
1998-04-21 |
St. Jude Children's Research Hospital |
Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
|
|
US6087486A
(en)
|
1996-01-29 |
2000-07-11 |
The Trustees Of The University Of Pennsylvania |
Nucleotide sequences encoding vpr receptor protein
|
|
US6060587A
(en)
|
1996-01-29 |
2000-05-09 |
The Trustees Of The University Of Pennsylvania |
Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
|
|
US5649652A
(en)
|
1996-02-16 |
1997-07-22 |
Sackett; Eleanor L. |
Clothes hanger with storage hook
|
|
ATE309366T1
(de)
*
|
1996-02-22 |
2005-11-15 |
Merck & Co Inc |
Synthetische hiv-gene
|
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
AU728422B2
(en)
|
1996-06-21 |
2001-01-11 |
Merck & Co., Inc. |
Vaccines comprising synthetic genes
|
|
US5951975A
(en)
|
1996-06-28 |
1999-09-14 |
University Of Pittsburgh |
Induction of CTLs specific for natural antigens by cross priming immunization
|
|
EP0942747A1
(en)
|
1996-08-26 |
1999-09-22 |
Chiron Corporation |
Postinfection human immunodeficiency virus (hiv) vaccination therapy
|
|
CA2265889A1
(en)
|
1996-09-06 |
1998-03-12 |
The Regents Of The University Of California |
E25a protein, methods for production and use thereof
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
US6139833A
(en)
|
1997-08-08 |
2000-10-31 |
Lexicon Genetics Incorporated |
Targeted gene discovery
|
|
US5830697A
(en)
|
1997-01-21 |
1998-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
P-glycoprotein mutant resistant to cyclosporin modulation
|
|
EE9900343A
(et)
*
|
1997-02-07 |
2000-02-15 |
Merck & Co., Inc. |
Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
|
|
US5990091A
(en)
|
1997-03-12 |
1999-11-23 |
Virogenetics Corporation |
Vectors having enhanced expression, and methods of making and uses thereof
|
|
AU6535898A
(en)
|
1997-03-14 |
1998-10-12 |
President And Fellows Of Harvard College |
Glycosylation deficient siv and hiv envelope glycoproteins
|
|
RO120148B1
(ro)
|
1997-03-14 |
2005-09-30 |
Idec Pharmaceuticals Corporation |
Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
|
|
JP2001519070A
(ja)
|
1997-03-24 |
2001-10-16 |
クイーンズ ユニバーシティー アット キングストン |
一致検出の方法、製品および装置
|
|
AU754242B2
(en)
|
1997-04-28 |
2002-11-07 |
Arsinur Burcoglu |
Method of treating HIV infection and related secondary infections thereof
|
|
US5858675A
(en)
|
1997-05-13 |
1999-01-12 |
Incyte Pharmaceuticals, Inc. |
Double-stranded RNA-binding protein
|
|
US6099847A
(en)
|
1997-05-15 |
2000-08-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Chimeric Gag pseudovirions
|
|
AU8160298A
(en)
|
1997-06-23 |
1999-01-04 |
Emory University |
Human immunodeficiency viruses causing aids in a nonhuman primate
|
|
CA2296067C
(en)
|
1997-07-09 |
2008-10-07 |
The University Of Queensland |
Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
|
|
CA2298438C
(en)
|
1997-08-01 |
2010-10-05 |
Genetic Systems Corporation |
Synthetic antigen for the detection of antibodies immunoreactive with hiv virus
|
|
WO1999012416A1
(en)
|
1997-09-09 |
1999-03-18 |
The Trustees Of Columbia University In The City Of New York |
T-independent conjugate-vaccines
|
|
EP1028712B1
(en)
|
1997-09-19 |
2005-01-12 |
Shire Laboratories Inc. |
Solid solution beadlet
|
|
US5932442A
(en)
|
1997-09-23 |
1999-08-03 |
Incyte Pharmaceuticals, Inc. |
Human regulatory molecules
|
|
US5932445A
(en)
|
1997-11-07 |
1999-08-03 |
Incyte Pharmaceuticals, Inc. |
Signal peptide-containing proteins
|
|
FR2773156B1
(fr)
|
1997-12-26 |
2000-03-31 |
Biovacs Inc |
Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
|
|
CA2320513A1
(en)
|
1998-02-11 |
1999-08-19 |
Joseph T. Bruder |
Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors
|
|
GB9803351D0
(en)
|
1998-02-17 |
1998-04-15 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
|
WO1999053046A2
(en)
|
1998-04-14 |
1999-10-21 |
Chiron Corporation |
Noncloning technique for expressing a gene of interest
|
|
CA2328180A1
(en)
|
1998-04-14 |
1999-10-21 |
Merck & Co., Inc. |
Needleless administration of polynucleotide formulations
|
|
ATE315653T1
(de)
|
1998-04-22 |
2006-02-15 |
Chiron Corp |
Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
|
|
US6090388A
(en)
|
1998-06-20 |
2000-07-18 |
United Biomedical Inc. |
Peptide composition for prevention and treatment of HIV infection and immune disorders
|
|
FR2780069B1
(fr)
|
1998-06-23 |
2002-06-28 |
Inst Nat Sante Rech Med |
Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
|
|
BR9912732A
(pt)
|
1998-08-03 |
2001-11-27 |
Univ Montana |
Estrutura molecular isolada, vìrus envelopadorecombinante, formilação de vacina, anticorpomonoclonal, anti-soro policlonal, geléia, espuma,creme ou unguento contraceptivo, amostras desangue de mamìfero e de humano, kit, linhagemcelular, processos de tratamento ou deprevenção de infecção por um vìrus em sujeito, detratamento ou de prevenção de infecção por hivem um humano, de inibição de infecção por um vìrusem uma amostra de sangue, de inibição de infecçãopor hiv em uma amostra de sangue humano, dedescontaminação de ferramentas cirúrgicas oudentais, de monitoração de produto de anticorpopara a estrutura molecular, de produção de umimunógeno para uso em uma vacina para otratamento ou a prevenção de infecção por umvìrus, e de produção de um imunólogeno para usoem uma vacina para o tratamento ou a prevençãode infecção por hiv, estrutura reticulada,anticorpo monoclonal para a estrutura, dedescontaminação de ferramentas cirúrgicas oudentais, processo de seleção de uma estruturamolecular para eficácia de vacina, mamìfero,complexo de proteìna isolado, formulação devacina, processos de imunização de um animal paraum vìrus, e de preparação de um complexo deproteìna, células fixadas, processos depurificação de um complexo de proteìna e detratamento de um hospedeiro que tem sidoexposto a um vìrus, ou de prevenção de infecçãode um hospedeiro pelo citado vìrus, e composição.
|
|
AU6139699A
(en)
*
|
1998-09-11 |
2000-04-03 |
Children's Medical Center Corporation |
Packaging cell lines for hiv-derived retroviral vector particles
|
|
AU5980899A
(en)
|
1998-09-25 |
2000-04-17 |
Smithkline Beecham Biologicals (Sa) |
Novel compounds
|
|
CA2344558A1
(en)
|
1998-10-09 |
2000-04-20 |
Dynavax Technologies Corporation |
Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
|
|
US6489542B1
(en)
|
1998-11-04 |
2002-12-03 |
Monsanto Technology Llc |
Methods for transforming plants to express Cry2Ab δ-endotoxins targeted to the plastids
|
|
ATE384795T1
(de)
|
1998-12-31 |
2008-02-15 |
Novartis Vaccines & Diagnostic |
Modifizierte hiv env polypeptide
|
|
AU2221600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
EP1141314A2
(en)
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
CA2360352A1
(en)
|
1999-01-27 |
2000-08-03 |
Stratagene |
Methods and compositions for high level expression of a heterologous protein with poor codon usage
|
|
WO2000029561A2
(en)
|
1999-03-29 |
2000-05-25 |
Statens Serum Institut |
Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
|
|
AU778106B2
(en)
|
1999-04-26 |
2004-11-18 |
K.U. Leuven Research & Development |
Synthetic gene for expressing active retroviral protein in eukaryotes
|
|
MXPA01011137A
(es)
|
1999-05-03 |
2003-07-14 |
Uab Research Foundation |
Inmunizacion genetica no invasiva, productos de la expresion a partir de esta, y sus usos.
|
|
AP1891A
(en)
|
1999-05-06 |
2008-09-23 |
The Immune Response Corp |
HIV immunogenic compositions and methods.
|
|
KR100773109B1
(ko)
|
1999-05-06 |
2007-11-02 |
웨이크 포리스트 유니버시티 |
면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
|
|
US6420545B1
(en)
|
1999-05-24 |
2002-07-16 |
The Trustees Of The University Of Pennsylvania |
CD4-independent HIV envelope proteins as vaccines and therapeutics
|
|
US6280989B1
(en)
|
1999-06-17 |
2001-08-28 |
Dmitri Kapitonov |
Sialyltransferases
|
|
JP2003530307A
(ja)
|
1999-07-06 |
2003-10-14 |
メルク・アンド・カンパニー・インコーポレーテッド |
gag遺伝子保有アデノウイルスHIVワクチン
|
|
US7479285B1
(en)
|
1999-08-19 |
2009-01-20 |
Dynavax Technologies Corporation |
Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
|
|
CA2392010A1
(en)
|
1999-08-27 |
2001-03-08 |
Regents Of The University Of California |
Use of lentiviral vectors for antigen presentation in dendritic cells
|
|
WO2001019958A2
(en)
|
1999-09-17 |
2001-03-22 |
Dana-Farber Cancer Institute, Inc. |
Stabilized soluble glycoprotein trimers
|
|
CA2384828A1
(en)
|
1999-09-21 |
2001-03-29 |
Zivko Nikolov |
Methods for producing recombinant proteins
|
|
ATE454901T1
(de)
|
1999-10-13 |
2010-01-15 |
Novartis Vaccines & Diagnostic |
Verfahren zur erhaltung zellimmuneantworten gegen proteinen
|
|
CA2387646A1
(en)
|
1999-10-21 |
2001-04-26 |
Kalobios, Inc. |
A general method for optimizing the expression of heterologous proteins
|
|
EP1228237A1
(en)
|
1999-11-01 |
2002-08-07 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
|
KR20020059727A
(ko)
|
1999-11-13 |
2002-07-13 |
플레믹 크리스티안 |
고차 핵산 기재 구조
|
|
WO2001042308A2
(en)
|
1999-12-08 |
2001-06-14 |
Novartis Ag |
Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
|
|
AU782193B2
(en)
|
1999-12-17 |
2005-07-07 |
Merck & Co., Inc. |
Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
|
|
WO2001045748A1
(en)
|
1999-12-22 |
2001-06-28 |
Merck & Co., Inc. |
Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
|
|
JP4627950B2
(ja)
|
1999-12-23 |
2011-02-09 |
アメリカ合衆国 |
変異HIVgag/pol、SIVgagおよびSIVenv遺伝子を持つ分子クローン
|
|
DK1240186T3
(da)
|
1999-12-23 |
2010-05-31 |
Medical Res Council |
Forbedringer i eller relateret til immunrespons mod HIV
|
|
AU2001233063A1
(en)
|
2000-01-31 |
2001-08-07 |
Aaron Diamond Aids Research Center |
Vaccination of hiv infected persons following highly active antiretroviral therapy
|
|
JP2003529559A
(ja)
|
2000-01-31 |
2003-10-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
新規用途
|
|
AU2001238501A1
(en)
|
2000-02-16 |
2001-08-27 |
Bechtel Bwxt Idaho, Llc |
Selective destruction of cells infected with human immunodeficiency virus
|
|
CA2402440A1
(en)
|
2000-02-18 |
2001-08-23 |
University Of Washington |
Aids ancestral viruses and vaccines
|
|
US20030138453A1
(en)
|
2000-09-28 |
2003-07-24 |
O'hagan Derek |
Microparticles for delivery of heterologous nucleic acids
|
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|